FDA Approves Mirdametinib for Neurofibromatosis Type 1 Dr. Kamal Kant Kohli13 Feb 2025 7:00 AM ISTThe US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for adults and children aged 2 and older with neurofibromatosis type 1...
Reduction of cutaneous Neurofibroma number on face may improve QoL in individuals with neurofibromatosis type1: JAMA Dr Riya Dave15 Nov 2024 9:30 PM ISTResearchers have found that the presence and severity of cutaneous neurofibromas, especially those on the face, significantly lower the quality of...
AstraZeneca Koselugo gets Chinese nod for paediatric patients with neurofibromatosis type 1, plexiform neurofibromas Ruchika Sharma9 May 2023 12:30 PM ISTIn addition to China, Koselugo is also approved in the US, EU, Japan and several other countries for the treatment of paediatric patients with NF1 and...
selumetinib effective, safe in kids with symptomatic and inoperable plexiform neurofibromas Dr. Shravani Dali9 April 2022 10:00 AM ISTSelumetinib is effective and safe in children with symptomatic and inoperable plexiform neurofibromas (PN), according to a recent study published in...
AstraZeneca Pharma India bags DCGI nod to import and market Selumetinib capsules Ruchika Sharma27 Sept 2021 4:02 PM ISTNew Delhi: Drugmaker, AstraZeneca Pharma India Limited, has recently announced that the company has received import and market permission in Form...
